Business Context and Reporting Period
This Form 8-K was filed by 22nd Century Group, Inc. on December 3, 2019. The filing primarily reports the entry into a material definitive agreement to acquire an equity stake in Panacea Life Sciences, Inc. ("PLS"), alongside significant changes to the Company's Board of Directors and executive management.
Key Financial Metrics and Transaction Details
The filing details a complex investment structure rather than standard operating financial metrics. Key transaction values include:
- Initial Investment: $12 million in cash plus 1,297,017 shares of 22nd Century Group common stock.
- Acquired Assets (Initial): 3,733,334 shares of PLS Series B Preferred Stock, a $7,000,000 secured convertible note, and a warrant to purchase additional Series B Preferred Stock.
- Purchase Price: $1.875 per share for Series B Preferred Stock.
- Ownership Stake: 15.2% of PLS on a fully diluted basis immediately following the initial closing.
- Convertible Note Terms: $7 million principal, 10% annual interest, secured by a lien on all PLS assets.
Material Changes and Milestone Obligations
The agreement includes contingent future obligations based on PLS performance:
- Milestone Closing: If PLS achieves $20 million in gross revenues over any 12 consecutive months, 22nd Century Group must purchase an additional 5,333,334 shares of Series B Preferred Stock.
- Milestone Payment: $8.5 million in cash plus common stock valued at $1.5 million (based on 30-day VWAP, floor $1.00).
- Resulting Ownership: Upon milestone completion, 22nd Century Group's ownership would increase to 30.4% of PLS on a fully diluted basis.
- Warrant Exercise: The Company holds a warrant to purchase enough Series B Preferred Stock to reach 51% ownership of PLS, exercisable after five years or upon PLS achieving $200 million in gross revenues for two consecutive fiscal years.
Management Commentary, Risks, and Personnel Changes
Personnel Changes:
- Board Departure: Dr. Joseph Alexander Dunn, a Board member since 2011, passed away.
- CFO Transition: Andrea S. Jentsch was promoted from Director of Accounting and Financial Reporting to Chief Financial Officer. John T. Brodfuehrer is transitioning from CFO to Vice President of Strategy in preparation for retirement.
Risks and Contingencies:
- Capital Expenditure Risk: The Company faces potential future cash outflows of $8.5 million and equity issuance if PLS revenue milestones are met.
- Put Right Obligation: Under a Side Agreement, if a "Fundamental Transaction" occurs after the warrant is fully exercised, the Company may be obligated to purchase PLS shares owned by Quintel-MC Incorporated (owned by PLS's CEO) for 1.5 times their invested capital ($17 million), totaling approximately $25.5 million.
- Dividend Rights: Series B Preferred Stock accrues 10% cumulative dividends, payable only when declared by PLS's Board.
Investor Verification Checklist
- Verify the current cash position of 22nd Century Group to assess liquidity for the initial $12 million payment and potential future milestone payments.
- Review the full text of the Side Agreement (Exhibit 10.4) to understand the specific triggers for the $25.5 million Put Right obligation to Quintel.
- Monitor PLS's gross revenue reports to determine if the $20 million milestone triggering the second closing is achievable.
- Confirm the valuation of the 1,297,017 common shares issued as part of the initial purchase price and the impact on existing shareholders.
- Assess the financial health of PLS, as the $7 million convertible note is secured by PLS assets, which may be at risk if PLS fails to meet revenue targets.